Earnings ·
Amylyx Pharmaceuticals reported a net loss of $43.4 million, or $0.39 per share, for the quarter ended June 30, 2026…
AMLXAmylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals reported a net loss of $43.4 million, or $0.39 per share, for the quarter ended June 30, 2026, compared to a $41.4 million loss in the prior year period. Research and development expenses decreased to $23.8 million from $27.2 million, primarily due to reduced spending on AMX0035 for progressive supranuclear palsy, partially offset by increased costs for avexitide clinical development. Selling, general, and administrative expenses rose to $21.9 million from $15.6 million, driven by higher legal fees and commercial strategic investments. The company held $250.8 million in cash equivalents and short-term investments at quarter-end, with a projected cash runway extending into 2028. Clinically, the final participant completed the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia, with topline data anticipated in late August or early September 2026. Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for rare endocrine and neurodegenerative diseases.